|
06 Mar 2020 |
Orionis Biosciences Debuts with Major Pharmaceutical Collaboration to Tackle Industry’s Most Challenging Protein Targets
|
|
04 Mar 2020 |
Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology
|
|
04 Mar 2020 |
Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
|
|
04 Mar 2020 |
Iktos and SRI International Announce Collaboration to Combine Artificial Intelligence and Novel Automated Discovery Platform for Accelerated Development of New Anti-Viral Therapies
|
|
02 Mar 2020 |
Gilead to Acquire Forty Seven for $4.9 Billion
|
|
29 Feb 2020 |
Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform
|
|
29 Feb 2020 |
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
|
|
26 Feb 2020 |
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries
|
|
26 Feb 2020 |
Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease
|
|
25 Feb 2020 |
Peptilogics Announces CARB-X Funding to Accelerate Development of First-in-Class Antibiotics to Address the Global Threat of Multi-drug Resistant Bacteria
|
|
25 Feb 2020 |
Bicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies
|
|
24 Feb 2020 |
Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)
|
|
20 Feb 2020 |
Tocagen and Forte Biosciences Announce Merger
|
|
20 Feb 2020 |
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMA
|
|
20 Feb 2020 |
Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs
|
|
19 Feb 2020 |
Nimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
|
|
12 Feb 2020 |
OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico
|
|
10 Feb 2020 |
Blue Water Vaccines Licenses Patent Rights for Streptococcus Pneumoniae Vaccine Development from St. Jude Children's Research Hospital
|
|
06 Feb 2020 |
Atreca Announces Strategic Research Collaboration with Merck to Identify Novel Antibody Targets in Oncology
|
|
05 Feb 2020 |
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
|
|
04 Feb 2020 |
SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)
|
|
04 Feb 2020 |
EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion
|
|
03 Feb 2020 |
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders
|
|
03 Feb 2020 |
IMIDomics and Gossamer Bio Enter into a Strategic Collaboration to Advance the Development of Novel Treatments for Patients with Immune-Mediated Inflammatory Diseases
|
|
29 Jan 2020 |
Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement
|
